|
|
|
Market Research Report
|
ADHD Therapeutics published by Global Industry Analysts, Inc. in June, 2010. This report consists of Pages: 321 and the price starts from US $ 3950.
Abstract
This report analyzes the worldwide markets for ADHD Therapeutics in US$
Million. The report provides separate comprehensive analytics for the US and
Rest of World. Annual estimates and forecasts are provided for each region for
the period of 2006 through 2015. The report profiles 27 companies including
many key and niche players such as Eli Lilly & Company, Johnson & Johnson,
Janssen-Cilag, Novartis AG, Shire Plc, UCB S.A., Companies with Drugs in
Pipeline for ADHD: Abbott Laboratories, Inc., Cortex Pharmaceuticals, Inc.,
KemPharm, Inc., and NeuroSearch A/S. Market data and analytics are derived
from primary and secondary research. Company profiles are mostly extracted
from URL research and reported select online sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
- A Prelude
- Lack of Awareness - A Major Impediment
- Adult ADHD - A Growing Market Opportunity
- Table 1: Market Share of ADHD Prescriptions by Age Category: Children,
Adolescents and Adults (includes corresponding Graph/Chart)
- Unfulfilled Needs Provide Impetus to Develop New Molecules
- Safety Concerns Foster Research in Non Stimulant Segment
- Presence of Co-morbidities with ADHD Creates Opportunities for Combination
Therapies
- Introduction of Generics Shakes Market
- Patent Expiries of Major Drugs in the ADHD Market
2. COMPETITIVE SCENARIO
- Table 2: Leading Brands in the Global ADHD Market by Prescription Share
(2008) (includes corresponding Graph/Chart)
- Shire Leads the Way
- J&J' s Concerta - Leading Drug for ADHD by Default
- Eli Lilly' s Strattera - Creating a Niche
- Novartis Retains Market Share
- Pipeline Drugs
3. THE ADHD CONUNDRUM
- ADHD - A Disorder or Marketing Gimmick of Phararketing Gimmick of Pharmaceutical Companies?
- Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market
- Differences in Diagnostic Criteria in Europe and US
- Hiccups in the Way
- ADHD in Women
4. ADHD - AN INSIGHT
- Attention Deficit Hyperactivity Disorder (ADHD) - Introduction
- Brief History of the Disorder
- Common Co-Occurring Disorders With ADHD
- Consequences of ADHD
- What Leads to ADHD?
- Study Reveals Deficits in Protein Levels in Brain' s Reward/Motivation
System
- ADHD Symptoms
- DSM IV Criteria for Diagnosis of ADHD
- DSM IV Criteria for Inattention and Hyperactivity/ Impulsivity
- Types of ADHD
- Treating ADHD
- Stimulants
- Non-stimulants
- Others
5. REVIEW OF SELECT DRUGS
- ADHD Drugs - Background
- Brand Review
- Ritalin LA
- Focalin
- Table 3: Global Revenues of Novartis' ADHD Drugs - Ritalin/Focalin
(2008-2009) (in US$ million)
- Concerta
- Table 4: Global Revenues of Concerta (2006-2009) (includes corresponding
Graph/Chart)
- Strattera
- Table 5: Global Revenues of Strattera (2006-2009) (in US$ million)
(includes corresponding Graph/Chart)
- Metadate CD
- Table 6: Global Revenues of Metadate CD/Equasym (2007-2008) (in
€Million)
- Adderall XR
- Table 7: Global Revenues of Adderall XR (2006-2009) (in US$ million)
(includes corresponding NeuroSearch Completes Phase II Studies on Efficacy
and Security of ABT-894 in Adults with ADHD
- Abbott Announces Positive Results From Phase II Studies of a Novel
Approach of Treating ADHD
7. PRODUCT LAUNCHES/INTRODUCTIONS
- Shire Unveils First Prodrug Therapy for ADHD in Canadian Market
- Teva Launches First Authorized Generic Version of Adderall XR® Capsules
- Shire Introduces INTUNIV™
- Eli Lilly Japan Introduces Strattera in the Country
8. RECENT INDUSTRY ACTIVITY
- Avacta Group Acquires TheraGenetics
- AstraZeneca Grants Interim Payment to Targacept
- Addrenex Pharmaceuticals Inks Agreement with Dream Pharma
- Durect Signs Agreement with Orient Pharma
- Hisamitsu Pharmaceutical Acquires Noven Pharmaceutical
- Shire Receives FDA Approval for INTUNIV Tablets
- Shire Pharmaceuticals and GSK Sign a Co-Promotion Deal for Vyvanse
- Shire Pharmaceuticals Establishes Office in Tokyo
- Shire and UCB Enter into Agreement
- Shire Retains Exclusivity for Vyvanse
- Shire Settles Litigation with Sandoz for Generic Adderall
- Sciele Pharma to Takeover Addrenex Pharmaceuticals
- Auriga Laboratories Receives Approval from FDA for Liquadd™
- Concerta Extended Release Tablets Receive US FDA Approval for Use in Adult
Treatment
- Eurand Enters into Settlement with UCB
- Paladin Labs Secures Dexedrine' s Distribution Rights from GlaxoSmithKline
- Shire Receives Approval from FDA for Use of Vyvanse in Adults
- Strattera Receives FDA Approval for Maintenance of ADHD in Children &
Adolescents
- The Dore Group Providing Alternate ADHD Treatment to Drugs Goes Into
Liquidation
- Shire Takes Over New River Pharmaceuticals to Gain Full Control Over
Vyvanse™
9. FOCUS ON SELECT PLAYERS
- Eli Lilly & Company (USA)
- Johnson & Johnson (USA)
- Janssen-Cilag (Switzerland)
- Novartis AG (Switzerland)
- Shire Plc (The UK)
- UCB S.A. (Belgium)
- Companies with Drugs in Pipeline for ADHD
- Abbott Laboratories, Inc. (USA)
- Cortex Pharmaceuticals, Inc. (US)
- KemPharm, Inc. (USA)
- NeuroSearch A/S (Denmark)
10. GLOBAL MARKET PERSPECTIVE
- Table 10: World Recent Past, Current & Future Analysis for Attention
Deficit Hyperactivity Disorder (ADHD) by Geographic Region - US and Rest of
World Markets Independently Analyzed with Annual Revenues in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 11: World 10 -Year Perspective for Attention Deficit Hyperactivity
Disorder (ADHD) Market by Geographic Region - Percentage Breakdown of Revenues
for US and Rest of World Markets for Years 2006, 2009 and 2015
III. MARKET
1. THE UNITED STATES
- A. Market Analysis
- Current and Future Analysis
- ADHD Epidemic in the US !
- Table 12: Prevalence Rate of ADHD in Different Backgrounds According
to Age, Ethnicity, Gender and Family Structure in the US in 2007
- Causes for Widespread ADHD Diagnosis and Treatment in the US
- ADHD Drugs Combat Safety Concerns
- Market Exhibits Greater Potential
- Table 13: Percentage Share of ADHD Prescriptions in US by Patient
Category - Children, Adolescents and Adults (2002 and 2007) (includes
corresponding Graph/Chart)
- Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market
- Cyclical Nature of ADHD Market
- Competitive Scenario
- Table 14: Leading Players and Drug Brands in the US ADHD Market (2007,
2008) : Percentage Breakdown of Prescriptions for Shire, McNeil Janssen,
Eli Lilly, Novartis, Celltech, Pharmaceuticals / UCB, and Others (includes
corresponding Graph/Chart)
- Product Launches
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 15: US Recent Past, Current & Future Analysis for Sales Force
Automation (SFA) Market Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2006 through 2015 (includes corresponding
Graph/Chart)
2. REST OF WORLD
- A. Market Analysis
- Current and Future Analysis
- Review of Select Markets
- Canada
- Concerta Leads the Market
- Table 16: Leading Drug Brands in the Canadian ADHD Market (2008):
Percentage Share Breakdown of Revenues for Concerta, Adderall, Dexedrine,
Generics, and Others (includes corresponding Graph/Chart)
- Europe
- Germany
- Table 17: Prevalence Rates of ADHD in Germany in Terms of Gender, Age
and Socioeconomic Status Reimbursement Policy
- The United Kingdom
- Australia
- Product Launches
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 18: Rest of World Recent Past, Current & Future Analysis for
Attention Deficit Hyperactivity Disorder (ADHD) Drugs Analyzed with Annual
Revenues in US$ Million for Years 2006 through 2015 (includes corresponding
Graph/Chart)
IV. COMPETITIVE LANDSCAPE
|
 |
